Please use this identifier to cite or link to this item:
Title: Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
Authors: Louza, Mario Rodrigues
Elkis, Helio
Ruschel, Sandra
Oliveira, Irismar Reis de
Bressan, Rodrigo Affonseca [UNIFESP]
Belmonte-de-Abreu, Paulo
Grabowski, Hamilton
Appolinario, Jose Carlos
Universidade de São Paulo (USP)
Hosp Mario Kroeff
Universidade Federal da Bahia (UFBA)
Universidade Federal de São Paulo (UNIFESP)
Univ Fed Rio Grande do Sul
Hosp Bom Retiro
Janssen Cilag Farmaceut Ltda
Keywords: patient compliance
delayed-action preparations
Issue Date: 1-Jan-2011
Publisher: Dove Medical Press Ltd
Citation: Neuropsychiatric Disease and Treatment. Albany: Dove Medical Press Ltd, v. 7, p. 391-398, 2011.
Abstract: Background: Long-acting injectable antipsychotics may improve medication adherence, thereby improving overall treatment effectiveness. This study aimed to evaluate the effectiveness, safety, and tolerability of risperidone long-acting injection in schizophrenic patients switched from oral antipsychotic medication.Methods: in a 12-month, multicenter, open-label, noncomparative study, symptomatically stable patients on oral antipsychotic medication with poor treatment adherence during the previous 12 months received intramuscular injections of risperidone long-acting injection (25 mg starting dose) every 2 weeks. the primary endpoint was the change in Positive and Negative Syndrome Scale (PANSS) total score.Results: of the 60 patients who were screened, 53 received at least one injection (safety population), and 51 provided at least one postbaseline assessment. Mean PANSS total scores improved significantly throughout the study and at endpoint. Significant improvements were also observed in Clinical Global Impression of Severity, Personal and Social Performance, and Drug Attitude Inventory scales. Risperidone long-acting injection was safe and well-tolerated. Severity of movement disorders on the Extrapyramidal Symptom Rating Scale was reduced significantly. the most frequently reported adverse events were insomnia (22.6%), increased prolactin (17.0%), and weight gain (13.2%).Conclusion: Risperidone long-acting injection was associated with significant symptomatic improvements in stable patients with schizophrenia following a switch from previous antipsychotic medications.
ISSN: 1176-6328
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.